## **INVITED SPEAKER SEMINAR**

## Adjunct 5-hydroxytryptophan slow-release (5-HTP SR) for treatment -resistant depression: Deduced from human data, confirmed in mice

Dr. Jacob Jacobsen will talk about a novel antidepressant augmentation principle, which will have a short path from bench to bedside. This is important because intractable treatment-resistant depression is a major unmet need affecting tens of millions worldwide. Dr. Jacobsen is a Senior Research Associate from the Laboratory of Dr. Marc Caron, Duke University and has previously held positions at Lundbeck Pharma and NeuroSearch Biotech.

Depression is a leading cause of disability globally (WHO). Selective serotonin-reuptake inhibitors (SSRIs) remain the mainstay of antidepressant treatment. Yet, less than 50% of patients remit. Sadly, the antidepressant pipeline is thin. Any improved treatments will benefit the lives of millions.

5-HTP is the immediate, rate-limiting precursor to serotonin. There is evidence that 5-HTP is an antidepressant in humans, in particular as augmentation treatment to serotonergic antidepressants. The human safety record is good, with no severe side effects ever reported. However, 5-HTP is rapidly absorbed and rapidly eliminated. This makes 5-HTP utterly 5-HTP impractical for chronic antidepressant treatment and curtails the therapeutic potential. However, an advanced slow-release (SR) formulation could remedy 5-HTP's drugability limitations and transform 5-HTP into the drug 5-HTP SR.


In mice, this is exactly what Dr. Jacobsen and colleagues find. Adjunct 5-HTP SR to chronic SSRI treatment robustly augments the serotonin neurochemical/pharmacodynamic and "antidepressant-like" behavioral effects. In an extensive screen of side effects adjunct 5-HTP SR caused none. In contrast, adjunct conventional 5-HTO immediate release could not produce this therapy-like profile in mice.

Speaker:	<b>Dr. Jacob Jacobsen</b> Laboratory of Prof Marc Caron, Department of Cell Biology Duke University Medical Center, Durham, NC
Hosts:	Prof David M. Epstein &Director, Center for Technology & DevelopmentProf Shirish ShenolikarInterim Director for Neuroscience & Behavioral Disorders Program
Date:	Wednesday, 15th Oct 2014
Time:	<b>12:00 - 1:00 pm</b> (Light refreshments will be served at 11:30am)
Venue:	Meeting Room 7C, Level 07 Duke-NUS Graduate Medical School
t Person:	Ms Shanti Rajaram, Office of Research Tel: 6516 7266 or Email: shanti.rajaram@duke-nus.edu.sg

Contac

Dr. Jacobsen represents a group of investigators at Duke University who is visiting Duke-NUS. He is interested in developing new therapeutic approaches for treatment resistant depression. He hopes to move 5-HTP SR towards becoming a clinical reality in Singapore and Asia.

Duke-NUS, CTeD, NBD and DUNES is sponsoring this presentation as part of it's drive to foster innovation and collaboration.



Duke-NUS Graduate Medical School Singapore 8 College Road Singapore 169857 Tel: 6516 7666 Fax: 62216932 www.duke-nus.edu.sg . A school of the National University of Singapore (RCB No: 200604346E)







